TCGA-33-4532-01A-01R-1201-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.640
- MYC_TARGETS_V1+0.620
- E2F_TARGETS+0.580
- G2M_CHECKPOINT+0.510
- MTORC1_SIGNALING+0.430
- OXIDATIVE_PHOSPHORYLATION+0.390
- DNA_REPAIR+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.300
- FATTY_ACID_METABOLISM+0.240
- SPERMATOGENESIS+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.680
- INTERFERON_GAMMA_RESPONSE-0.590
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- TNFA_SIGNALING_VIA_NFKB-0.510
- INFLAMMATORY_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.490
- ALLOGRAFT_REJECTION-0.460
- COMPLEMENT-0.450
- KRAS_SIGNALING_UP-0.410
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.945 |
| 2 | SRR975602 | — | — | 0.944 |
| 3 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.944 |
| 4 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.942 |
| 5 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.940 |
| 6 | ERR2208894 | — | — | 0.933 |
| 7 | C3N-00555 | — | cohortSQ2 | 0.930 |
| 8 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.928 |
| 9 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.927 |
| 10 | C3L-00993 | — | cohortSQ1 | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.640 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.620 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |